⚡️Neurotech Brief⚡️
Paradromics launched the Connect-One early feasibility study for Connexus, a fully implantable brain-computer interface designed to restore speech in patients with severe paralysis. FDA IDE approval was granted for the trial.
Trial locations: The clinical study is being conducted at three sites: Sacramento CA, Boston MA, and Ann Arbor MI. These sites represent leading institutions in neurology and neurotech research.
Clinical significance: The Connexus system represents progress toward functional restoration for severely paralyzed patients, with fully implantable design potentially improving quality of life and long-term usability compared to external systems.
@Paradromics
Source: Paradromics